<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "http://jats.nlm.nih.gov/publishing/1.0/JATS-journalpublishing1.dtd">
<article article-type="abstract" dtd-version="1.0" xml:lang="en" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CC</journal-id>
<journal-id journal-id-type="nlm-ta">Cardiol Croat</journal-id>
<journal-title-group>
<journal-title>Cardiologia Croatica</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Cardiol. Croat.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="ppub">1848-543X</issn>
<issn pub-type="epub">1848-5448</issn>
<publisher><publisher-name>Croatian Cardiac Society</publisher-name></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">CC 2024 19_11-12_452</article-id>
<article-id pub-id-type="doi">10.15836/ccar2024.452</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Extended Abstract</subject></subj-group>
<subj-group subj-group-type="subheading"><subject>Heart failure</subject></subj-group>
</article-categories>
<title-group>
<article-title>MicroRNAs as potential biomarkers of heart failure</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0005-5097-3411</contrib-id><name><surname>&#x017D;upani&#x0107;</surname><given-names>Juraj</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1">*</xref></contrib>
<contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-9137-3014</contrib-id><name><surname>Gjuras</surname><given-names>Karlo</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6768-9218</contrib-id><name><surname>&#x017D;arak</surname><given-names>Marko</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib>
<aff id="aff1"><label>1</label><institution>University of Zagreb</institution>, <institution content-type="dept">Faculty of Pharmacy and Biochemistry</institution>, <addr-line>Zagreb</addr-line>, <country country="hr">Croatia</country></aff>
<aff id="aff2"><label>2</label><institution>Health Centre Bjelovar-Bilogora County, Bjelovar</institution>, <country country="hr">Croatia</country></aff>
<aff id="aff3"><label>3</label><institution>Dubrava University Hospital</institution>, <addr-line>Zagreb</addr-line>, <country country="hr">Croatia</country></aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>*</label>ADDRESS FOR CORRESPONDENCE: Juraj &#x017D;upani&#x0107;, Farmaceutsko-biokemijski fakultet, Ante Kova&#x010D;i&#x0107;a 1, HR-10000 Zagreb, Croatia. / Phone: +385-91-7672-690 / E-mail: <email xlink:href="juraj.zupanic@gmail.com">juraj.zupanic@gmail.com</email></corresp></author-notes>
<pub-date date-type="pub" publication-format="electronic"><month>11</month><year>2024</year></pub-date>
<pub-date date-type="pub" publication-format="print"><month>11</month><year>2024</year></pub-date>
<volume>19</volume>
<issue>11-12</issue>
<fpage>452</fpage>
<lpage>452</lpage>
<history>
<date date-type="received"><day>29</day><month>09</month><year>2024</year></date>
<date><day>31</day><month>10</month><year>2024</year></date>
</history>
<permissions>
<copyright-statement>Croatian Cardiac Society</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Croatian Cardiac Society</copyright-holder>
</permissions>
<kwd-group kwd-group-type="author"><title>KEYWORDS: </title><kwd>biomarkers</kwd><kwd>heart failure</kwd><kwd>microRNA</kwd></kwd-group>
</article-meta>
</front>
<body>
<p><bold>Introduction</bold>: Heart failure (HF) affects 38 million people globally, contributing to increasing hospitalization rates and placing a significant burden on healthcare systems worldwide. Routinely used biomarkers for diagnosis, therapy monitoring, and evaluation of HF are B-type natriuretic peptide (BNP) and its N-terminal prohormone&#x2019;s fragment of B-type natriuretic peptide (NT-proBNP); however, both have limitations. (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>-<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>) Therefore, it is important to discover new biomarkers for early diagnosis. MicroRNAs (miRNA, miR) are small, non-coding ribonucleic acids with around 22 nucleotides. They are involved in the posttranscriptional regulation of numerous genes. (<xref ref-type="bibr" rid="r2"><italic>2</italic></xref>) Their stability, non-invasive availability, high sensitivity, and specificity for disease make them promising biomarkers for various pathological states, including HF. (<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>)</p>
<p><bold>Method</bold>s: The PubMed database was searched using the keywords &#x201C;microRNA&#x201D; and &#x201C;heart failure&#x201D;. The analysis included systematic reviews and meta-analyses published from 2019 to 2024.</p>
<p><bold>Results</bold>: According to the research, several miRNAs (miR-21, miR-30c, miR-210-3p, let-7i-5p, miR-129, let-7e-5p, and miR-622) were identified as potential biomarkers for HF diagnosis. (<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>) Studies also indicate that the expression of specific miRNAs is positively or negatively correlated with the New York Heart Association functional class and left ventricular ejection fraction (LVEF), which may be valuable for evaluating the severity and prognosis of HF. (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>, <xref ref-type="bibr" rid="r2"><italic>2</italic></xref>) Panels of various miRNAs have demonstrated high sensitivity and specificity in distinguishing between HF with reduced and preserved LVEF. (<xref ref-type="bibr" rid="r2"><italic>2</italic></xref>)</p>
<p><bold>Conclusion</bold>: MicroRNAs have big potential as novel biomarkers of HF. (<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>) They remain unusable in routine diagnostics due to issues including unstandardized methods for measuring their expression and long turnaround times. However, when combined with well-known biomarkers and diagnostic tools like BNP, NT-proBNP, and echocardiography, they could enable earlier and more precise diagnoses and better monitoring of patients with HF. (<xref ref-type="bibr" rid="r2"><italic>2</italic></xref>)</p>
</body>
<back>
<ref-list>
<title>LITERATURE</title>
<ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Figueiredo</surname><given-names>R</given-names></name><name><surname>Ad&#x00E3;o</surname><given-names>R</given-names></name><name><surname>Leite-Moreira</surname><given-names>AF</given-names></name><name><surname>M&#x00E2;ncio</surname><given-names>J</given-names></name><name><surname>Br&#x00E1;s-Silva</surname><given-names>C</given-names></name></person-group>. <article-title>Candidate microRNAs as prognostic biomarkers in heart failure: A systematic review.</article-title> <source>Rev Port Cardiol</source>. <year>2022</year> October;<volume>41</volume>(<issue>10</issue>):<fpage>865</fpage>&#x2013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1016/j.repc.2021.03.020</pub-id><pub-id pub-id-type="pmid">36207069</pub-id></mixed-citation></ref>
<ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parvan</surname><given-names>R</given-names></name><name><surname>Hosseinpour</surname><given-names>M</given-names></name><name><surname>Moradi</surname><given-names>Y</given-names></name><name><surname>Devaux</surname><given-names>Y</given-names></name><name><surname>Cataliotti</surname><given-names>A</given-names></name><name><surname>da Silva</surname><given-names>GJJ</given-names></name></person-group>. <article-title>Diagnostic performance of microRNAs in the detection of heart failure with reduced or preserved ejection fraction: a systematic review and meta-analysis.</article-title> <source>Eur J Heart Fail</source>. <year>2022</year> December;<volume>24</volume>(<issue>12</issue>):<fpage>2212</fpage>&#x2013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1002/ejhf.2700</pub-id><pub-id pub-id-type="pmid">36161443</pub-id></mixed-citation></ref>
<ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>NN</given-names></name><name><surname>Wang</surname><given-names>JL</given-names></name><name><surname>Fu</surname><given-names>YP</given-names></name></person-group>. <article-title>The microRNA Expression Profiling in Heart Failure: A Systematic Review and Meta-Analysis.</article-title> <source>Front Cardiovasc Med</source>. <year>2022</year> June 15;<volume>9</volume>:<elocation-id>856358</elocation-id>. <pub-id pub-id-type="doi">10.3389/fcvm.2022.856358</pub-id><pub-id pub-id-type="pmid">35783849</pub-id></mixed-citation></ref>
</ref-list>
</back>
</article>
